La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Arbutus Biopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Arbutus Biopharma..

Arbutus Biopharma (NASDAQ:ABUS) Azioni, Catena delle Opzioni

Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

Health Care

Press Releases

Arbutus Provides 2025 Corporate and Financial Update

News

Management

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Legal

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Earnings

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

General

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

ABUS

ROIV

AnaptysBio

Ardelyx

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Inhibrx Biosciences

Kodiak Sciences

Kura Oncology

MiMedx Group

Nanobiotix

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Replimune Group

Rezolute

Sana Biotechnology

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Tango Therapeutics

Tyra Biosciences

UroGen Pharma

Vir Biotechnology

Xencor

Chardan Capital

HC Wainwright & Co.

Jefferies

JMP Securities

Comments

Arbutus Biopharma

Arbutus Biopharma (ABUS) Opzioni

Arbutus Biopharma (NASDAQ:ABUS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO